Schaumburg, IL, April 12, 2024 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery Association (ASDSA) calls on states to strengthen patient safety through increased oversight of medical care in all settings. Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee emphasize the patient safety risks associated with receiving medical procedures in unlicensed, unapproved settings without proper oversight of medical care. These reported cases highlight the need for increased public protection measures, like the recommendations in ASDSA’s “Medical Spa Safety Act” to ensure patients’ safety.
With the growing public demand for facial fillers and neuromodulators, providing patients with optimal safety is a primary goal for ASDSA. The U.S. Food and Drug Administration (FDA) issued a guidance in 2023 to state that anyone considering a neurotoxin or dermal filler should consult with a licensed provider who is experienced in injecting dermal fillers; knowledgeable about fillers, anatomy, managing complications; and knows the risks and benefits of treatment.
“ASDSA takes the safety of patients very seriously, and we urge states to consider this in regulating medical practice in all settings of care. It is important to make sure all patients receive FDA approved products and not counterfeit or otherwise unsafe treatments,” said ASDSA President Seth Matarasso, MD. “Lack of regulation and enforcement has enabled many to offer medical procedures for cosmetic purposes outside of their training and expertise.”
“The Illinois Dermatological Society (IDS) stresses the critical need for cosmetic medical procedures to be performed by physicians with specialized training or those who follow established medical protocols under physician guidance. The recent botulism-like cases in Illinois are a stark reminder of the risks associated with unauthorized practitioners,” said IDS President Amy Derick, MD. “We stand with ASDSA and align with state health authorities in advocating for patients to receive treatments exclusively from licensed professionals employing FDA-approved products. This approach is fundamental to maintaining the utmost standards of patient safety and quality of care.”
ASDSA encourages patients and regulatory authorities to always consider safety first.
# # #
About the American Society for Dermatologic Surgery (ASDSA)
With a membership of 6,400+ physicians, ASDSA is a 501(c) (6) association, dedicated to education and advocacy on behalf of dermatologic surgeons and their patients. For more information, visit asds.net/ASDSA.
Follow @ASDSAdvocacy on Facebook, X (Twitter), Instagram and Threads!
